Skip to main content
Evidence Snapshot

LIM domain kinase 1

CHEMBL3836 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3836
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats LIM domain kinase 1 as ChEMBL target CHEMBL3836, mapped to UniProt P53667. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
LIM domain kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3836
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P53667
LIM domain kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why LIM domain kinase 1 matters

As of 2026-09-13

LIM domain kinase 1 is reviewed as LIM domain kinase 1 (UniProt P53667); the current evidence base includes 16 approved drugs, 1831 compounds, and 290 assays, with lead potency reaching pChEMBL 9.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 1831 compounds, and 290 assays for this target. The dominant activity type is KI. CHEMBL3623439 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL3623439 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why LIM domain kinase 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P53667, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1831
Total Compounds
290
Total Assays
16
Approved Drugs
IC50: 517.0, KI: 833.0, EC50: 2.0, KD: 399.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3623439
 9.5 IC50 —
No preferred name
CHEMBL5278261
 9.5 IC50 —
No preferred name
CHEMBL570126
 9.3 IC50 —
No preferred name
CHEMBL2070615
 9.0 IC50 —
No preferred name
CHEMBL3623442
 9.0 IC50 —

Approved Drugs

Structure Compound First Approval
CAPIVASERTIB
CHEMBL2325741
 2023
FEDRATINIB
CHEMBL1287853
 2019
ENCORAFENIB
CHEMBL3301612
 2018
DABRAFENIB
CHEMBL2028663
 2013
REGORAFENIB
CHEMBL1946170
 2012
CRIZOTINIB
CHEMBL601719
 2011
PAZOPANIB
CHEMBL477772
 2009
DASATINIB
CHEMBL5416410
 2006
SORAFENIB
CHEMBL1336
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3836